Allergy Therapeutics plc, a biotechnology company specializing in allergy vaccines, has announced a delay in the publication of its Annual Report and Accounts for the year ended June 30, 2023. The delay is due to additional time required by the company's auditor, BDO LLP, to complete the audit process. As a result, the company will not be able to meet the deadline of December 31, 2023, for publishing its annual report and accounts, as required by AIM Rule 19. Consequently, the company's ordinary shares will be temporarily suspended from trading on AIM starting from January 2, 2024.

The company aims to complete the final audit and publish its annual report and accounts as soon as possible, with an anticipated completion date by the end of January 2024. The temporary suspension of the company's ordinary shares will remain in effect until the requirements of AIM Rule 19 are satisfied.

For further information, please visit the company's website at www.allergytherapeutics.com.

This announcement contains inside information for the purposes of the UK Market Abuse Regulations.